Perceptic, a startup founded by former Palantir executives, has emerged from stealth with $12 million in seed funding to develop an end-to-end AI platform for drug development. The funding round was led by London-based venture capital firm Accel, with participation from Air Street Capital and Elder Gull, the company announced today (fortune.com).
The startup’s founders include Tilman Flock, a bioscience researcher and former Palantir AI platform lead. Perceptic’s software aims to automate the entire drug development process, from discovery through clinical trial design. The company has already secured multiple top-tier pharmaceutical clients, including Australian biotechnology firm CSL. The seed round will support further development of its platform, which differentiates itself by addressing the full drug development pipeline rather than isolated stages.
This funding round highlights growing investor interest in AI-driven drug discovery, a sector that has seen numerous startups like Isomorphic, Recursion, and Insilico Medicine emerge in recent years. However, no AI-discovered drugs have yet completed human clinical trials and gained regulatory approval, raising questions about the technology’s current impact. Perceptic’s comprehensive approach may address some limitations seen in earlier efforts focused on discrete parts of the process (fortune.com).
Looking ahead, Perceptic plans to expand its platform capabilities and deepen partnerships with pharmaceutical companies. The company did not disclose its valuation or specific timelines but aims to accelerate drug development by integrating AI across all stages, potentially improving efficiency and success rates in bringing new drugs to market (fortune.com).